Milestone Pharmaceuticals (MIST) Income towards Parent Company (2018 - 2022)
Milestone Pharmaceuticals (MIST) posted Income towards Parent Company of -$15.0 million for Q3 2022, up 10.57% on a QoQ basis from -$16.8 million in Q2 2022, and down 5.66% year-over-year from -$15.9 million in Q3 2021.
Milestone Pharmaceuticals (MIST) Income towards Parent Company (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals' Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$15.0 million for Q3 2022.
- Quarterly Income towards Parent Company fell 5.66% year-over-year to -$15.0 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$15.0 million (up 68.63% YoY) and the FY2021 annual result came in at -$42.9 million, up 14.24% from the prior year.
- Income towards Parent Company was -$15.0 million for Q3 2022 at Milestone Pharmaceuticals, up from -$16.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $770000.0 in Q2 2021 and bottomed at -$18.3 million in Q4 2019.
- A 5-year average of -$11.3 million and a median of -$12.7 million in 2019 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2021 — Income towards Parent Company soared 105.93% — and 2022, when it tumbled 2282.6%.
- Milestone Pharmaceuticals' Income towards Parent Company stood at -$9.7 million in 2018, then tumbled by 88.21% to -$18.3 million in 2019, then jumped by 52.61% to -$8.7 million in 2020, then tumbled by 94.83% to -$16.9 million in 2021, then grew by 10.98% to -$15.0 million in 2022.
- Business Quant data shows MIST's Income towards Parent Company at -$15.0 million in Q3 2022, -$16.8 million in Q2 2022, and -$16.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Milestone Pharmaceuticals | 147.87 Mn | -36.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -15.03 Mn |
| Jun 30, 2022 | -16.81 Mn |
| Dec 31, 2021 | -16.88 Mn |
| Sep 30, 2021 | -14.23 Mn |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -11.98 Mn |
| Jun 30, 2020 | -12.98 Mn |
| Mar 31, 2020 | -16.34 Mn |
| Dec 31, 2019 | -18.29 Mn |
| Sep 30, 2019 | -12.83 Mn |
| Jun 30, 2019 | -13.66 Mn |
| Mar 31, 2019 | -10.45 Mn |
| Dec 31, 2018 | -9.72 Mn |
| Sep 30, 2018 | -5.70 Mn |
| Jun 30, 2018 | -3.59 Mn |
| Mar 31, 2018 | -4.18 Mn |